Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison

Clifford, Cole; Jung, Richard G.; Hibbert, Benjamin; Chong, Aun Yeong; Lordkipanidzé, Marie; Tanguay, Jean‐François; So, Derek

doi:10.1080/09537104.2021.1904134

Cited by 3 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The measurement of blood thrombogenicity by T-TAS using AR chip is known to be affected by anticoagulants, GPIIb/IIIa antagonists, and GPIbα antagonists 15,20 but not by aspirin and P2Y12 antagonists, i.e., clopidogrel, prasugrel, and ticagrelor. 17,19,25,26 The reason for this has been mentioned in prior literature that P2Y12 inhibitors may have no effect in AR chip, in which thrombus formation is more dependent upon fibrin formation, as platelets play little in thrombus formation at low shear rates. 17 AR chip measures the formation of occlusive thrombus in a capillary channel coated with type I collagen and tissue thromboplastin, mimicking the formation of occlusive thrombus in the atherosclerotic artery.…”

Section: Discussionmentioning

confidence: 99%

Temporary Rise in Blood Thrombogenicity in Patients with Acute Myocardial Infarction

Kosugi

Ueda

Abe

et al. 2021

TH Open

View full text Add to dashboard Cite

Objective: Although blood thrombogenicity seems to be one of the determinant factors for the development of acute myocardial infarction (MI), it has not been dealt with in-depth. This study aimed to investigate blood thrombogenicity and its change in acute MI patients. Methods and Results: We designed a prospective, observational study that included 51 acute MI patients and 83 stable coronary artery disease (CAD) patients who underwent cardiac catheterization, comparing thrombogenicity of whole blood between: (1) acute MI patients and stable CAD patients; and (2) acute and chronic phase in MI patients. Blood thrombogenicity was evaluated by the Total Thrombus-Formation Analysis System (T-TAS) using the area under the flow pressure curve (AUC30) for the AR-chip. Acute MI patients had significantly higher AUC30 than stable CAD patients (median [interquartile range], 1771 [1585 - 1884] vs. 1677 [1527 - 1756], p = 0.010). Multivariate regression analysis identified acute MI with initial TIMI flow grade 0/1 as an independent determinant of high AUC30 (β = 0.211, p = 0.013). In acute MI patients, AUC30 decreased significantly from acute to chronic phase (1859 [1550 - 2008] to 1521 [1328 - 1745], p=0.001). Conclusion: Blood thrombogenicity was significantly higher in acute MI patients than in stable CAD patients. Acute MI with initial TIMI flow grade 0/1 was significantly associated with high blood thrombogenicity by multivariate analysis. In acute MI patients, blood thrombogenicity was temporarily higher in acute phase than in chronic phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Temporary Rise in Blood Thrombogenicity in Patients with Acute Myocardial Infarction

Kosugi

Ueda

Abe

et al. 2021

TH Open

View full text Add to dashboard Cite

show abstract

“…Therefore, to some extent, T-TAS reflects physiological conditions. A number of studies have reported its potential utility in assessment of antiplatelet drugs, e.g., aspirin, clopidogrel, PAR-1 and PAR-4 antagonists [9,15,22,25,27,28,42] and antithrombotic agents, e.g., direct thrombin and factor Xa inhibitors [10,21,26,40,48,50]. T-TAS has also demonstrated high sensitivity in detecting coagulation disorders such as haemophilia and vWD [32,34,37,[53][54][55][56][57][58], as well as platelet function defects for example, such as storage pool disease [6].…”

Section: Discussionmentioning

confidence: 99%

“…From the data obtained, it was possible to conclude that the best treatment regimen to prevent blood clots is DAPT. Summarizing their research, the authors suggest that DP guarantees antithrombotic synergism with the help of anticoagulant action (without isolated antiplatelet synergism) [28].…”

Section: Studymentioning

confidence: 99%

See 1 more Smart Citation

The Use of Total Thrombus Formation Analysis System as a Tool to Assess Platelet Function in Bleeding and Thrombosis Risk—A Systematic Review

Sikora

Karczmarska-Wódzka

Bugieda

et al. 2021

IJMS

View full text Add to dashboard Cite

Background. Today there are many devices that can be used to study blood clotting disorders by identifying abnormalities in blood platelets. The Total Thrombus Formation Analysis System is an automated microchip flow chamber system that is used for the quantitative analysis of clot formation under blood flow conditions. For several years, researchers have been using a tool to analyse various clinical situations of patients to identify the properties and biochemical processes occurring within platelets and their microenvironment. Methods. An investigation of recent published literature was conducted based on PRISMA. This review includes 52 science papers directly related to the use of the Total Clot Formation Analysis System in relation to bleeding, surgery, platelet function assessment, anticoagulation monitoring, von Willebrand factor and others. Conclusion. Most available studies indicate that The Total Thrombus Formation Analysis System may be useful in diagnostic issues, with devices used to monitor therapy or as a significant tool for predicting bleeding events. However, T-TAS not that has the potential for diagnostic indications, but allows the direct observation of the flow and the interactions between blood cells, including the intensity and dynamics of clot formation. The device is expected to be of significant value for basic research to observe the interactions and changes within platelets and their microenvironment.

show abstract

Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma

et al. 2023

View full text Add to dashboard Cite

Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison

Cited by 3 publications

References 19 publications

Temporary Rise in Blood Thrombogenicity in Patients with Acute Myocardial Infarction

Temporary Rise in Blood Thrombogenicity in Patients with Acute Myocardial Infarction

The Use of Total Thrombus Formation Analysis System as a Tool to Assess Platelet Function in Bleeding and Thrombosis Risk—A Systematic Review

Dual antiplatelet therapy inhibits neutrophil extracellular traps to reduce liver micrometastases of intrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About